This page provides access to the complete catalogue of MARA Ratings® — independent, committee-reviewed Reimbursement Risk Assessments designed for high-stakes Pharma Market Access decisions across therapeutic areas, indications, and launch stages.
Each listing represents a standardized Reimbursement Risk Assessment, calibrated against historical Health Technology Assessment (HTA) decisions and real-world payer outcomes across the US, EU4, UK, and Japan. The framework aligns clinical evidence, cost-effectiveness, and quality-of-life impact within a structured Pharma Market Access risk model.
MARA Ratings are not opinions.
They are structured, evidence-linked Reimbursement Risk Assessments that reduce variance in pricing, reimbursement, and market access assumptions before major capital allocation, licensing, M&A, or launch commitments are made.
These findings highlight key considerations not only for clinical outcomes but for payer response, pricing expectations, and reimbursement pathways — all of which shape market access risk in pharma and
These findings highlight key considerations not only for clinical outcomes but for payer response, pricing expectations, and reimbursement pathways — all of which shape market access risk in pharma and
These findings highlight key considerations not only for clinical outcomes but for payer response, pricing expectations, and reimbursement pathways — all of which shape market access risk in pharma and
These findings highlight key considerations not only for clinical outcomes but for payer response, pricing expectations, and reimbursement pathways — all of which shape market access risk in pharma and
These findings highlight key considerations not only for clinical outcomes but for payer response, pricing expectations, and reimbursement pathways — all of which shape market access risk in pharma and